BILN 2061

Known as: BILN 2061 ZW, BILN-2061, BILN2061 
 

Topic mentions per year

Topic mentions per year

1981-2017
024619812017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
ITX 5061 is a scavenger receptor B1 antagonist that has entered phase 1 clinical trials in hepatitis C virus (HCV)-infected… (More)
Is this relevant?
2009
2009
Hepatitis C virus (HCV) protease inhibitors targeting HCV NS3 can efficiently suppress HCV replication. However, the selection of… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
UNLABELLED Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2008
2008
An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis… (More)
Is this relevant?
2008
2008
Chronic hepatitis C virus (HCV) infection remains a major global health burden while current interferon-based therapy is… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2008
2008
We report here that dramatic improvement of the key RCM reaction in the synthesis of HCV protease inhibitor BILN2061 can be… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The recent establishment of a robust hepatitis C virus (HCV) cell culture system permits analysis of virus-host interactions… (More)
Is this relevant?
2006
2006
Compounds with in vitro anti-hepatitis C virus (HCV) activity are often advanced directly into clinical trials with limited or no… (More)
Is this relevant?
2005
2005
BILN-2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower… (More)
Is this relevant?
2005
2005
Compounds A-782759 (an N-1-aza-4-hydroxyquinolone benzothiadiazine) and BILN-2061 are specific anti-hepatitis C virus (HCV… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 4
Is this relevant?